Dr. Ariel Feldstein is a Professor of Pediatrics (with Tenure) at UC San Diego School of Medicine. He is a leading physician scientist, innovator and serial entrepreneur. After graduating from the Univ. of Buenos Aires and completing a postdoctoral program in physiology at the Mayo Clinic, Dr. Feldstein went on to become the Director of Research for the Pediatric Institute at the Cleveland Clinic (2008-2011) before moving to San Diego to become Chief of the Division of Gastroenterology, Hepatology & Nutrition at Rady Children’s Hospital and UCSD (2011-2019). Dr. Feldstein has published over 190 peer-reviewed publications in top medical journals. His research laboratory has provided key evidence regarding the role of cell death, innate immune activation and inflammatory responses driven by Inflammasomes during chronic tissue injury, fibrosis and carcinogenesis. He is an innovator with a number of issued patents including the development of soluble cytokeratin-18 as a diagnostic biomarker for NASH. He is a serial entrepreneur being the founder of three Biotech Companies, Torrey Pines Metabolic Health Labs, Jecure Therapeutics (acquired by Genentech/Roche in 2018), and Elgia Therapeutics.